The first phase of the trial includes a cohort of healthy volunteers between the ages of 18 and 55. This phase is now advancing to include healthy subjects between the ages of 65 and 85; its phase II/III will explore effective vaccine dose. The vaccine is based on a proprietary replication-defective simian adenoviral vector that encodes the full-length coronavirus spike protein, according to the firm.

The GRAd vector belongs to species C adenovirus that are considered the most potent vaccine carriers and has low seroprevalence in humans. This means that GRAd vaccine immunogenicity is not affected by preexisting anti-human adenovirus antibodies.

ReiThera designed the study in collaboration with the Lazzaro Spallanzani National Institute for Infectious Diseases (INMI) in Rome, Italy; it has been financially supported by the Italian Ministry of Scientific Research, also in Rome and is being conducted at the institute and the GB Rossi University Hospital in Verona.

AstraZeneca COVID-19 vaccine achieves 70% efficacy
AstraZeneca released interim analysis from clinical trials of AZD1222, its COVID-19 vaccine candidate in the U.K. and Brazil, with data demonstrating...

Dr. Anthony Fauci breaks down the importance of COVID-19 vaccines
Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, discussed the perils and opportunities of public trust...

Pfizer, BioNTech just days away from applying for EUA for COVID-19 vaccine
Pfizer and BioNTech have passed another milestone in their effort to deliver a vaccine for the SARS-CoV-2 virus. The companies on November 18 reported...

Moderna reports EMA review of COVID-19 vaccine candidate, U.K. supply deal
Moderna said that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use has initiated a rolling review of the firm's messenger...

U.S. government expands assistance to J&J COVID-19 vaccine research
The Biomedical Advanced Research and Development Authority is expanding its partnership with Johnson & Johnson by providing additional support for...